Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs

References

• Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the central brain tumor registry of the United States, 1990–1994. Neuro Oncol. 1999;1:14–25.
   PubMedGoogle Scholar
• Willis J, Smith C, Ironside JW, et al. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol. 2005;31:141–149.
   PubMed Web of Science ®Google Scholar
• Palma L, Celli P, Franco C, et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg. 1997;86:793–800.
   PubMed Web of Science ®Google Scholar
• Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16:829–840.
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86:845–852.
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840–844.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107:315–321.
   PubMed Web of Science ®Google Scholar
• Mazza E, Brandes A, Zanon S, et al. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2016;77:115–120.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78:271–276.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62:1210–1212.
   PubMed Web of Science ®Google Scholar
• Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15:75–77.
   PubMed Web of Science ®Google Scholar
• Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33:4093–4098.
   PubMed Web of Science ®Google Scholar
• Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96:211–217.
   PubMed Web of Science ®Google Scholar
• Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000;46:938–47; discussion 47–8.
   PubMed Web of Science ®Google Scholar
• Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS. 2011;119:831–843.
   PubMed Web of Science ®Google Scholar
• Panagopoulos AT, Lancellotti CL, Veiga JC, et al. Expression of cell adhesion proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol. 2008;89:73–87.
   PubMed Web of Science ®Google Scholar
• Hou J, Kshettry VR, Selman WR, et al. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013;35:E2.
   PubMed Web of Science ®Google Scholar
• Baumgarten P, Brokinkel B, Zinke J, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol. 2013;28:1157–1166.
   PubMed Web of Science ®Google Scholar
• Puchner MJ, Hans VH, Harati A, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21:2445–2446.
   PubMed Web of Science ®Google Scholar
• Ly KI, Hamilton SR, Rostomily RC, et al. Improvement in visual fields after treatment of intracranial meningioma with bevacizumab. J Neuroophthalmol. 2015;35:382–386.
   PubMed Web of Science ®Google Scholar
• Provias J, Claffey K, delAguila L, et al. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery. 1997;40:1016–1026.
   PubMed Web of Science ®Google Scholar
• Otsuka S, Tamiya T, Ono Y, et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol. 2004;70:349–357.
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Hama S, Taniguchi E, et al. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer. 1999;85:936–944.
   PubMed Web of Science ®Google Scholar
• Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol. 2010;99:315–324.
   PubMed Web of Science ®Google Scholar
• Goldman CK, Bharara S, Palmer CA, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery. 1997;40:1269–1277.
   PubMed Web of Science ®Google Scholar
• Kalkanis SN, Carroll RS, Zhang J, et al. Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. J Neurosurg. 1996;85:1095–1101.
   PubMed Web of Science ®Google Scholar
• Ding YS, Wang HD, Tang K, et al. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008;38:344–351.
   PubMed Web of Science ®Google Scholar
• Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013;8:e59941.
   PubMed Web of Science ®Google Scholar
• Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011;22:990–991.
   PubMed Web of Science ®Google Scholar
• Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74:136–141.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109:187–193.
   PubMed Web of Science ®Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63–70.
   PubMed Web of Science ®Google Scholar
• Furtner J, Schopf V, Seystahl K, et al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro Oncol. 2016;18:401–407.
   PubMed Web of Science ®Google Scholar
• Grimm SA, Kumthekar P, Chamberlain MC, et al. Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. J Clin Oncol. 2015;33: 2055–2055.
   Web of Science ®Google Scholar
• Shih KC, Chowdhary S, Rosenblatt P, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016;129:281–288.
   PubMed Web of Science ®Google Scholar
• DeBoer R, Grimm SA, Chandler J, et al. A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas. J Clin Oncol. 2008;26:2060.
   Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117:93–101.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17:116–121.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Samara Y, Codreanu I, et al. Systemic therapy for relapsed/refractory meningioma: is there potential for antiangiogenic agents? J Oncol Pharm Pract. 2018 Sep 26: 1078155218799850. DOI:10.1177/1078155218799850
   Web of Science ®Google Scholar
• Franke AJ, Skelton Iv WP, Woody LE, et al. Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int. 2018;9:133.
   PubMedGoogle Scholar